CTLA4 and hypophysitis: The risk of developing hypophysitis is strongly correlated with the specific class of ICI used, with the highest incidence with combined anti-CTLA-4 and anti-PD-1/PD-L1 agents, with rates from 6.4% to 19% [34,35].